← All trials
NCT05117177
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 14, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- Nov 11, 2021
- Last posted
- Nov 11, 2021
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- iTeos TherapeuticsLead sponsor
- Université catholique de LouvainOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.